Calluna Pharma announces €75 million Series A financing
Drug Discovery World
JANUARY 24, 2024
Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma. Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor.
Let's personalize your content